Alkermes Announces Amylin and Lilly Will Present More than 20 Studies for Exenatide at EASD 2009.

Business Wire › September 24, 2009

Linked as:

Extract

Alkermes Announces Amylin and Lilly Will Present More than 20 Studies for Exenatide at EASD 2009.

SAN DIEGO & INDIANAPOLIS & CAMBRIDGE, Mass. -- Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN), Eli Lilly and Company (NYSE: LLY) and Alkermes, Inc. (Nasdaq: ALKS) will unveil data from more than 20 studies at the 45th Annual Meeting of the European Association for the Study of Diabetes (EASD) in Vienna, Austria, taking place from Sept. 29 to Oct. 2. The companies will present the latest research findings on BYETTA([R]) (exenatide) injection and exenatide once weekly. The EASD annual meeting, which brings together more than 14,000 delegates, is the most important platform in Europe f...

See the full content of this document